Skip to Content
  • Previous Rank211
  • Revenues ($M)$48,851
  • Revenue Percent Change-1.5%
  • Profits ($M)$6,960
  • Profits Percent Change-23.8%
  • Assets ($M)$167,460
  • Employees97,900

Pfizer will have to find a way to boost profits that doesn’t entail cutting its tax bill. In early 2016, the U.S. Treasury Department scuttled its planned inversion with Ireland-based Allergan, which would have moved the Big Pharma company’s headquarters overseas. The New York-based drug maker, which benefited from its blockbuster medication Lipitor before it went off patent, was hoping to reduce its tax rate through the $150 billion deal, which would have been the largest pharmaceutical merger in history. Instead, Pfizer will have to focus on reviving its core business, which has been in decline. The company’s sales dropped 1.5% in 2015 as it still deals with the impact of patent expirations on some of its biggest drugs. Its profits, meanwhile, fell nearly 24%, largely due to a surge in acquisition-related costs, which more than quintupled from the previous year due to Pfizer’s purchase of Hospira in early 2015. Pfizer’s stock fell 14.2% in 2015, a result of its performance as well as concerns that drug price regulation.

Fortune Data StoreLooking for leads, investment insights, or competitive intelligence?Get Premium Access

Company Information

CEO
Ian C. Read
Sector
Health Care
Industry
Pharmaceuticals
HQ Location
New York, NY
Employees97,900
Websitehttp://www.pfizer.com
Years on Global 500 List22

Pfizer Rank History

Key Financials (last fiscal year)

($ Millions)% change
Revenues ($M)$48,851-1.5%
Profits ($M)$6,960-23.8%
Assets ($M)$167,460-
Total Stockholder Equity ($M)$64,720-

Profit Ratios

Profit as % of Revenues14.2%
Profits as % of Assets4.2%
Profits as % of Stockholder Equity10.8%